Zyprexa's restricted reimbursement is in dispute

Published: 2002-09-05 06:59:00

Updated: 2002-09-05 06:59:00

The Ministry of Health and Welfare announced its restricted reimbursement plan on Zyprexa (olanzapine) to take effect on September 1, to this effect that that if other inexpensive drugs compared to Zyprexa are ineffective in the treatment of psychosis, Zyprexa will be still under the current insu...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK